Tscan Therapeutics Inc (TCRX)

Dec 17, 2024

2 "Strong Buy"-Rated Biotech Stocks With 303% To 446% Upside Potential - Barchart

Dec 17, 2024

Dec 17, 2024

tScan Therapeutics sees $385,768 purchase by Lynx1 Capital - Investing.com

Dec 17, 2024

Dec 16, 2024

Lynx1 Capital Management LP Increases Stake in TScan Therapeutics Inc - GuruFocus.com

Dec 16, 2024

Dec 15, 2024

TScan Therapeutics' SWOT analysis: TCR-T stock shows promise amid challenges - Investing.com India

Dec 15, 2024

Dec 15, 2024

TScan Therapeutics' SWOT analysis: TCR-T stock shows promise amid challenges By Investing.com - Investing.com South Africa

Dec 15, 2024

Dec 14, 2024

Wedbush Cuts Earnings Estimates for TScan Therapeutics - Defense World

Dec 14, 2024

Dec 13, 2024

Equities Analysts Offer Predictions for TCRX FY2026 Earnings - MarketBeat

Dec 13, 2024

Dec 13, 2024

TScan Therapeutics (NASDAQ:TCRX) Earns Buy Rating from Needham & Company LLC - Defense World

Dec 13, 2024

Dec 13, 2024

HC Wainwright Reaffirms Buy Rating for TScan Therapeutics (NASDAQ:TCRX) - Defense World

Dec 13, 2024

Dec 12, 2024

TScan Therapeutics (NASDAQ: TCRX) Issues Report on Updated Phase 1 Trial Data for ALLOHA Program**On December 9, 2024, TScan Therapeutics, Inc. released a comprehensive report on the latest developments surrounding its ALLOHA ™ Phase 1 trial - Defense World

Dec 12, 2024

Dec 11, 2024

The Analyst Landscape: 5 Takes On TScan Therapeutics - Benzinga

Dec 11, 2024

Dec 11, 2024

HC Wainwright Reiterates Buy Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat

Dec 11, 2024

Dec 11, 2024

TScan Therapeutics (NASDAQ:TCRX) Receives Buy Rating from Needham & Company LLC - MarketBeat

Dec 11, 2024

Dec 10, 2024

TScan Therapeutics Announces Promising Phase 1 Trial Results - TipRanks

Dec 10, 2024

Dec 09, 2024

TScan Therapeutics to Present Updated Data from the Ongoing - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

Tscan Therapeutics to Present Updated Data from the Ongoing Alloha?? Phase 1 Heme Trial During Oral Session At the 66Th American Society of Hematology Annual Meeting and Exposition - Marketscreener.com

Dec 09, 2024

Dec 09, 2024

TScan's Blood Cancer Treatment Shows Breakthrough 92% Relapse Prevention in Phase 1 Trial Data - StockTitan

Dec 09, 2024

Dec 05, 2024

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years - GlobeNewswire

Dec 05, 2024

Dec 05, 2024

TScan Therapeutics Named Top Workplace in Massachusetts for Third Straight Year - StockTitan

Dec 05, 2024

Dec 02, 2024

TScan Therapeutics to Host Virtual KOL Event to Discuss - GlobeNewswire

Dec 02, 2024

Dec 02, 2024

TScan Therapeutics to Host KOL Event on Phase 1 Blood Cancer Trial Data at ASH - StockTitan

Dec 02, 2024

Nov 21, 2024

TScan issues stock in loan conversion - Investing.com

Nov 21, 2024

Nov 21, 2024

LMR Partners LLP Reduces Stock Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat

Nov 21, 2024

Nov 20, 2024

Tscan therapeutics sees $4,113 stock purchase by Lynx1 capital - Investing.com India

Nov 20, 2024

Nov 20, 2024

TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? - MSN

Nov 20, 2024

Nov 20, 2024

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 20, 2024

Nov 19, 2024

TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World

Nov 19, 2024

Nov 16, 2024

FY2024 Earnings Estimate for TCRX Issued By Lifesci Capital - Defense World

Nov 16, 2024

Nov 16, 2024

FY2024 EPS Estimate for TScan Therapeutics Lifted by Analyst - Defense World

Nov 16, 2024

Nov 15, 2024

TScan Therapeutics (NASDAQ:TCRX) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 15, 2024

Nov 15, 2024

Wedbush Research Analysts Boost Earnings Estimates for TCRX - MarketBeat

Nov 15, 2024

Nov 14, 2024

TScan Therapeutics Inc (TCRX) Quarterly 10-Q Report - Quartzy

Nov 14, 2024

Nov 14, 2024

Wedbush Has Positive Forecast for TCRX FY2028 Earnings - MarketBeat

Nov 14, 2024

Nov 14, 2024

TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts By Investing.com - Investing.com Nigeria

Nov 14, 2024

Nov 14, 2024

TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts - Investing.com India

Nov 14, 2024

Nov 14, 2024

TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 14, 2024

Nov 14, 2024

Needham & Company LLC Reaffirms “Buy” Rating for TScan Therapeutics (NASDAQ:TCRX) - Defense World

Nov 14, 2024

Nov 13, 2024

TScan Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 13, 2024

Nov 12, 2024

Tscan Therapeutics earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada

Nov 12, 2024

Nov 12, 2024

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 12, 2024

Nov 12, 2024

TScan Reports Zero Relapses in Key Trial Despite 74% Revenue Drop; $271M Cash Runway - StockTitan

Nov 12, 2024

Nov 07, 2024

New Blood Cancer Treatment Shows Continued Response - Streetwise Reports

Nov 07, 2024

Nov 07, 2024

Tscan Therapeutics Inc’s (TCRX) 7.56% Increase Justifies A Second Look - Stocks Register

Nov 07, 2024

Nov 06, 2024

TScan Therapeutics' (TCRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat

Nov 06, 2024

Nov 06, 2024

Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews - Benzinga

Nov 06, 2024

Nov 06, 2024

Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet? - Simply Wall St

Nov 06, 2024

Nov 06, 2024

TScan Therapeutics' SWOT analysis: innovative therapy stock faces pivotal year - Investing.com Australia

Nov 06, 2024

Nov 05, 2024

TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire

Nov 05, 2024

Nov 05, 2024

TScan's Blood Cancer Trial Shows Zero Relapses: Breakthrough Phase 1 Results | TCRX Stock News - StockTitan

Nov 05, 2024